Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2008, Article ID 265095, 8 pages
http://dx.doi.org/10.1155/2008/265095
Research Article

Inhibition of Angiogenic Factor Production from Murine Mast Cells by an Antiallergic Agent (Epinastine Hydrochloride) In Vitro

1Department of Physiology, School of NRS, Showa University, 1865 Toka-Ichiba, Midori-ku, Yokohama 226-8555, Japan
2Department of Otolaryngology, School of Medicine, Showa University, Shinagawa-ku, Tokyo, Japan

Received 28 February 2008; Accepted 30 June 2008

Academic Editor: Steven Kunkel

Copyright © 2008 K. Asano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. H. Howarth, M. Salagean, and D. Dokic, “Allergic rhinitis: not purely a histamine-related disease,” Allergy, vol. 55, no. 64, pp. 7–16, 2000. View at Publisher · View at Google Scholar
  2. R. J. Salib and P. H. Howarth, “Remodelling of the upper airways in allergic rhinitis: is it a feature of the disease?” Clinical & Experimental Allergy, vol. 33, no. 12, pp. 1629–1633, 2003. View at Publisher · View at Google Scholar
  3. J. Bousquet, W. Jacquot, A. M. Vignola, C. Bachert, and P. Van Cauwenberge, “Allergic rhinitis: a disease remodeling the upper airways?” Journal of Allergy and Clinical Immunology, vol. 113, no. 1, pp. 43–49, 2004. View at Publisher · View at Google Scholar
  4. K. Asano, K.-I. Kanai, and H. Suzaki, “Suppressive activity of fexofenadine hydrochloride on metalloproteinase production from nasal fibroblasts in vitro,” Clinical & Experimental Allergy, vol. 34, no. 12, pp. 1890–1898, 2004. View at Publisher · View at Google Scholar
  5. C. Ward and H. Walters, “Airway wall remodelling: the influence of corticosteroids,” Current Opinion in Allergy & Clinical Immunology, vol. 5, no. 1, pp. 43–48, 2005. View at Publisher · View at Google Scholar
  6. H. Yuksel, C. Kose, O. Yilmaz et al., “Increased expression of tissue vascular endothelial growth factor and foetal liver kinase-1 receptor in seasonal allergic rhinitis and relevance to asthma component,” Clinical & Experimental Allergy, vol. 37, no. 8, pp. 1183–1188, 2007. View at Publisher · View at Google Scholar
  7. I. Puxeddu, D. Ribatti, E. Crivellato, and F. Levi-Schaffer, “Mast cells and eosinophils: a novel link between inflammation and angiogenesis in allergic diseases,” Journal of Allergy and Clinical Immunology, vol. 116, no. 3, pp. 531–536, 2005. View at Publisher · View at Google Scholar
  8. M. Gaudry, O. Brégerie, V. Andrieu, J. El Benna, M.-A. Pocidalo, and J. Hakim, “Intracellular pool of vascular endothelial growth factor in human neutrophils,” Blood, vol. 90, no. 10, pp. 4153–4161, 1997. View at Google Scholar
  9. K. Iijima, N. Yoshikawa, and H. Nakamura, “Activation-induced expression of vascular permeability factor by human peripheral T cells: a non-radioisotopic semiquantitative reverse transcription-polymerase chain reaction assay,” Journal of Immunological Methods, vol. 196, no. 2, pp. 199–209, 1996. View at Publisher · View at Google Scholar
  10. T. Horiuchi and P. F. Weller, “Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5,” American Journal of Respiratory Cell and Molecular Biology, vol. 17, no. 1, pp. 70–77, 1997. View at Google Scholar
  11. E. Pinney, K. Liu, B. Sheeman, and J. Mansbridge, “Human three-dimensional fibroblast cultures express angiogenic activity,” Journal of Cellular Physiology, vol. 183, no. 1, pp. 74–82, 2000. View at Publisher · View at Google Scholar
  12. I. Puxeddu, A. Alian, A. M. Piliponsky, D. Ribatti, A. Panet, and F. Levi-Schaffer, “Human peripheral blood eosinophils induce angiogenesis,” International Journal of Biochemistry & Cell Biology, vol. 37, no. 3, pp. 628–636, 2005. View at Publisher · View at Google Scholar
  13. K. Norrby, “Mast cell and angiogenesis,” APMIS, vol. 110, no. 5, pp. 355–371, 2002. View at Publisher · View at Google Scholar
  14. J. Chodosh, “Human adenovirus type 37 and the BALB/c mouse: progress toward a restricted adenovirus keratitis model,” Transactions of the American Ophthalmological Society, vol. 104, no. 3, pp. 346–365, 2006. View at Google Scholar
  15. P. S. Muether, S. Dell, N. Kociok et al., “The role of integrin a5ß1 in the regulation of corneal neovascularization,” Experimental Eye Research, vol. 85, no. 3, pp. 356–365, 2007. View at Publisher · View at Google Scholar
  16. J. S. Kang, Y. D. Yoon, M. H. Han et al., “Estrogen receptor-independent inhibition of tumor necrosis factor-a gene expression by phytoestrogen equol is mediated by blocking nuclear factor-?B activation in mouse macrophages,” Biochemical Pharmacology, vol. 71, no. 1-2, pp. 136–143, 2005. View at Publisher · View at Google Scholar
  17. F. W. Fraunfelder, “Epinastine hydrochloride for atopic disease,” Drugs of Today, vol. 40, no. 8, pp. 677–683, 2004. View at Publisher · View at Google Scholar
  18. S. M. Whitcup, R. Bradford, J. Lue, R. M. Schiffman, and M. B. Abelson, “Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active-and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis,” Clinical Therapeutics, vol. 26, no. 1, pp. 29–34, 2004. View at Publisher · View at Google Scholar
  19. K.-I. Kanai, K. Asano, T. Hisamitsu, and H. Suzaki, “Suppressive activity of epinastine hydrochloride on TARC production from human peripheral blood CD4+ T cells in vitro,” Journal of Pharmacy and Pharmacology, vol. 57, no. 8, pp. 1027–1035, 2005. View at Publisher · View at Google Scholar
  20. K.-I. Kanai, K. Asano, S. Watanabe, Y. Kyo, and H. Suzaki, “Epinastine hydrochloride antagonism against interleukin-4-mediated T cell cytokine imbalance in vitro,” International Archives of Allergy and Immunology, vol. 140, no. 1, pp. 43–52, 2006. View at Publisher · View at Google Scholar
  21. Y. Herouy, P. Mellios, E. Bandemir et al., “Inflammation in stasis dermatitis upregulates MMP-1, MMP-2 and MMP-13 expression,” Journal of Dermatological Science, vol. 25, no. 3, pp. 198–205, 2001. View at Publisher · View at Google Scholar
  22. A. Shaida, G. Kenyon, J. Devalia, R. J. Davies, T. T. MacDonald, and S. L. F. Pender, “Matrix metalloproteinases and their inhibitors in the nasal mucosa of patients with perennial allergic rhinitis,” Journal of Allergy and Clinical Immunology, vol. 108, no. 5, pp. 791–796, 2001. View at Publisher · View at Google Scholar
  23. C. Svensson, M. Andersson, L. Greiff, U. Alkner, and C. G. A. Persson, “Exudative hyperresponsiveness of the airway microcirculation in seasonal allergic rhinitis,” Clinical & Experimental Allergy, vol. 25, no. 10, pp. 942–950, 1995. View at Publisher · View at Google Scholar
  24. S. Mori, S. Fujieda, H. Sunaga, S. B. Fox, and H. Saito, “Expression of platelet-derived endothelial cell growth factor and vascularity in the nasal mucosa from allergic rhinitis,” Clinical & Experimental Allergy, vol. 30, no. 11, pp. 1637–1644, 2000. View at Google Scholar
  25. E. J. Battegay, “Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects,” Journal of Molecular Medicine, vol. 73, no. 7, pp. 333–346, 1995. View at Publisher · View at Google Scholar
  26. F. Levi-Schaffer and J. Pe'Er, “Mast cells and angiogenesis,” Clinical & Experimental Allergy, vol. 31, no. 4, pp. 521–524, 2001. View at Publisher · View at Google Scholar
  27. M. Iwasaki, K. Saito, M. Takemura et al., “TNF-a contributes to the development of allergic rhinitis in mice,” Journal of Allergy and Clinical Immunology, vol. 112, no. 1, pp. 134–140, 2003. View at Publisher · View at Google Scholar
  28. J. He, T. Wang, L. Yao et al., “Construction and delivery of gene therapy vector containing soluble TNFa receptor-IgGFc fusion gene for the treatment of allergic rhinitis,” Cytokine, vol. 36, no. 5-6, pp. 296–304, 2006. View at Publisher · View at Google Scholar
  29. M. Bocheńska-Marciniak, M. Kupczyk, P. Górski, and P. Kuna, “The effect of recombinant interleukin-8 on eosinophils' and neutrophils' migration in vivo and in vitro,” Allergy, vol. 58, no. 8, pp. 795–801, 2003. View at Publisher · View at Google Scholar
  30. P. Gosset, I. Tillie-Leblond, F. Malaquin, J. Durieu, B. Wallaert, and A.-B. Tonnel, “Interleukin-8 secretion in patients with allergic rhinitis after an allergen challenge: interleukin-8 is not the main chemotactic factor present in nasal lavages,” Clinical & Experimental Allergy, vol. 27, no. 4, pp. 379–388, 1997. View at Publisher · View at Google Scholar
  31. G. Ciprandi, M. A. Tosca, G. L. Marseglia, and C. Klersy, “Relationships between allergic inflammation and nasal airflow in children with seasonal allergic rhinitis,” Annals of Allergy, Asthma and Immunology, vol. 94, no. 2, pp. 258–261, 2005. View at Google Scholar
  32. G. Ciprandi, I. Cirillo, A. Vizzaccaro, M. Milanese, and M. A. Tosca, “Nasal obstruction in patients with seasonal allergic rhinitis: relationships between allergic inflammation and nasal airflow,” International Archives of Allergy and Immunology, vol. 134, no. 1, pp. 34–40, 2004. View at Publisher · View at Google Scholar
  33. S. Yoshida, M. Ono, T. Shono et al., “Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis,” Molecular and Cellular Biology, vol. 17, no. 7, pp. 4015–4023, 1997. View at Google Scholar
  34. S. Klemm and J. Ruland, “Inflammatory signal transduction from the FcεRI to NF-κB,” Immunobiology, vol. 211, no. 10, pp. 815–820, 2006. View at Publisher · View at Google Scholar
  35. H.-Y. Shin, S.-H. Kim, H.-J. Jeong et al., “Epigallocatechin-3-gallate inhibits secretion of TNF-a, IL-6 and IL-8 through the attenuation of ERK and NF-?B in HMC-1 cells,” International Archives of Allergy and Immunology, vol. 142, no. 4, pp. 335–344, 2007. View at Publisher · View at Google Scholar
  36. C. Kamei, M. Akagi, M. Mio et al., “Antiallergic effect of epinastine (Wal 801 CL) on immediate hypersensitivity reactions: (I) elucidation of the mechanism for histamine release inhibition,” Immunopharmacology and Immunotoxicology, vol. 14, no. 1-2, pp. 191–205, 1992. View at Publisher · View at Google Scholar
  37. H. Mita and T. Shida, “Comparison of anti-allergic activities of the histamine H1 receptor antagonists epinastine, ketotifen and oxatomide in human leukocytes,” Arzneimittel-Forschung/Drug Research, vol. 45, no. 1, pp. 36–40, 1995. View at Google Scholar
  38. A. Sarashina, S. Tatami, N. Yamamura, Y. Tsuda, and T. Igarashi, “Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children,” British Journal of Clinical Pharmacology, vol. 59, no. 1, pp. 43–53, 2005. View at Publisher · View at Google Scholar